Free shipping on all orders over $ 500

Recaticimab

Cat. No. M25092
Recaticimab Structure
Synonym:

SHR-1209

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Receticimab mediates the degradation of PCSK9 by binding to PCSK9, increasing the level of low-density lipoprotein (LDL) receptors on the surface of hepatocytes, reducing the level of LDL in plasma, and achieving the goal of lowering blood lipids. Recaticimab has potential application in hypercholesterolemia.

Chemical Information
CAS Number 2361290-85-7
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Mingtong Xu, et al. BMC Med. PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study

Related PCSK9 Products
AZD0780

AZD0780 (PCSK9-IN-12, EX-A6975) is a heteroaryl compound. AZD0780 (PCSK9-IN-12, EX-A6975) has bind affinity for PCSK9 with a Kd value of <200 nM. AZD0780 (PCSK9-IN-12, EX-A6975) can be used for the research of cholesterol metabolism.

NNC0385-0434

NNC0385-0434 is an orally active peptide small molecule PCSK9 inhibitor for atherosclerosis-related studies.

CiVi-008

CiVi-008 is an orally active PCSK9 antisense oligonucleotide (ASO) inhibitor for studies related to disorders of lipid metabolism.

CiVi-007

CiVi-007 is an antisense oligonucleotide (ASO) polymerized with N-acetylglucosamine that targets PCSK9 and can be used in studies related to hypercholesterolemia.

AZD-8233

AZD-8233 is an orally active, antisense oligonucleotide (ASO) targeting PCSK9 that targets and inhibits the translation and protein synthesis of PCSK9 mRNA in hepatocytes and reduces circulating LDL-C levels. It can be used in studies related to hypercholesterolemia.

  Catalog
Abmole Inhibitor Catalog




Keywords: Recaticimab, SHR-1209 supplier, PCSK9, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.